The pan-neutralizing mouse monoclonal antibodies, 1D11 and 2G7, bind and reduce biological activity of all three TGF-β isoforms and have demonstrated therapeutic potential in mouse tumor models. This evidence concerns the gene TGFB1 and neoplasm.